Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians ...

Designation, together with a permanent HCPCS code effective October 1, 2026, supports patient access and reimbursement for PYLARIFY TruVu, Lantheus' PSMA PET imaging agentBEDFORD, Mass., Sept. 30, ...

Roughly 1 in 8 men receive a prostate cancer diagnosis at some stage in their lives, but only about 1 in 44 men will die of ...

Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians ...

Study advances development of Lantheus' investigational GRPR-targeted PET imaging program for prostate cancerBEDFORD, Mass., Sept. 28, 2026 (GLOBE NEWSWIRE) -- ("Lantheus" or the "Company") (NASDAQ: ...

People looking to stay healthy and tone up instead find themselves heading down a path of food restriction and guilt.

The first sub-study will support international research in the UK, US and South Africa, known as SAMBAI, aiming to understand factors that influence cancer outcomes in underserved populations of ...

Learn how to interpret your PSMA-PET scan results, understand SUV metrics, and track metastatic prostate cancer treatment options and progress.

Learn how prostate cancer is treated at each stage, from active surveillance and surgery to radiation, hormone therapy, and targeted drugs.

On Friday, a team of nine self-described "extremely average" golfers is attempting to cover that distance in just 24 hours, hitting golf balls almost continuously to raise money for Prostate Cancer UK ...

The combination of multiparametric MRI (mpMRI) and PSMA PET/CT has substantially advanced the diagnostic evaluation of men with suspected prostate cancer. As both modalities are increasingly ...